GLPwatch
Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.
J Diabetes Complications · 2022
Last updated 2026-05-28In a study of people with type 2 diabetes using multiple daily insulin injections, adding liraglutide increased insulin production by 19% after 24 weeks compared to a placebo. The effect was measured using C-peptide, a marker of insulin secretion.
AI summary of the abstract below.
| Journal | J Diabetes Complications, 2022 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.07 |
| NIH percentile | 6 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
In this post-hoc analysis of data from a randomised clinical trial, we compared the effect of liraglutide to placebo on markers of insulin secretion in persons with type 2 diabetes treated with multiple daily insulin injections. Liraglutide increased insulin secretion, measured by C-peptide, by 19% after 24 weeks of treatment. CLINICAL TRIAL REGISTRATION: EudraCT 2012-001941-42.
Verbatim abstract via PubMed 35101325 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.